Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 45 years old
- People of any gender (male or female)
- People who are able to understand the study information and agree to take part voluntarily
- People who have been formally diagnosed with schizophrenia using a standardised diagnostic interview (called the SCID-5)
Who may not be able to join:
- People who have had a drug or alcohol misuse disorder (other than caffeine, tobacco, or mild marijuana use) in the past six months, or who test positive for drugs at the start of the study
- People who have a current neurological condition, such as Parkinson's disease, epilepsy, or Multiple Sclerosis
- People who have had a head injury that caused them to lose consciousness
- People for whom the brain stimulation treatment used in this trial (called TMS) would not be safe — for example, those who have had seizures (other than childhood febrile seizures), have metal in their skull, have a cochlear implant, or have deep brain stimulation electrodes
- People for whom an MRI scan would not be safe — for example, those who have a pacemaker or other metal in their body
- People suspected to have an intellectual disability, based on a clinical interview and background history
- People who are pregnant
- People who have changed the type of antipsychotic medication they take in the last 30 days, or changed the dose in the last 14 days
- People taking certain medications that may interfere with the brain stimulation treatment — specifically, benzodiazepines at doses equivalent to 2 mg or more of lorazepam per day, or any anti-seizure (anticonvulsant) medication
- People who have already received five or more sessions of a similar type of brain stimulation treatment (rTMS or theta-burst) in the past six months
- People who are currently experiencing active thoughts of suicide, as measured by a specific clinical rating scale (confirm with trial site for exact details)
- People who score 7 or more on a scale that measures certain movement-related side effects sometimes associated with antipsychotic medication (confirm with trial site for exact details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stephanie Hare, PhD, University of Maryland, Baltimore
Phone: 410-402-6119
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The change in the short interval intracortical inhibition (SICI) score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.